• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Cloud AI Today - Novo Nordisk Partners With AWS For AI-Driven Drug Discovery

    Simply Wall St·08/11/2026 12:07:59
    Listen to the news

    Novo Nordisk has entered a strategic partnership with Amazon Web Services (AWS) to enhance drug discovery using artificial intelligence and cloud technologies. This collaboration includes establishing a co-innovation hub in London, which brings together AWS engineers, AI specialists, and Novo Nordisk's research and development teams to streamline the process of bringing new medicines to market. As part of this agreement, AWS becomes Novo Nordisk's preferred cloud provider and strategic AI partner, leveraging AWS's AI technologies to compress timelines from drug target identification to clinical trials. The partnership aims to modernize Novo Nordisk’s operations and harness AI-driven innovations across its efforts in treating chronic diseases.

    In other market news, Datadog (NasdaqGS:DDOG) was a standout up 11.5% and closing at $260.78. In the meantime, Lumentum Holdings (NasdaqGS:LITE) lagged, down 8.6% to finish the session at $813.51.

    Lumentum Holdings is poised for growth from booming cloud and AI demand with strategic expansions. Click to explore the detailed narrative on Lumentum Holdings' growth potential.

    For a timely dive into recent Cloud AI trends, don't miss our Market Insights article titled 'Earnings Season vs. AI,' where we unpack the SaaS sector's disruption risks and opportunities.

    Best Cloud AI Stocks

    • ServiceNow (NYSE:NOW) ended the day at $127.44 up 2%.
    • Microsoft (NasdaqGS:MSFT) finished trading at $506.06 up 1.2%. Blackbaud Inc. recently announced a new Copilot-enabled agent that integrates its Raiser's Edge NXT with Microsoft 365 applications, enhancing fundraising insights and decision-making, 1 day ago.
    • Alphabet (NasdaqGS:GOOGL) ended the day at $357.52 up 0.9%.

    Make It Happen

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Sources: